NVIDIA
NVDA
Tesla
TSLA
Taiwan Semiconductor
TSM
4
Palantir
PLTR
5
Advanced Micro Devices
AMD
US Stock MarketDetailed Quotes
RLAY Relay Therapeutics
- 3.085
- -0.115-3.59%
Trading Mar 4 10:37 ET
522.97MMarket Cap-1.31P/E (TTM)
3.185High3.020Low351.82KVolume3.120Open3.200Pre Close1.08MTurnover0.27%Turnover RatioLossP/E (Static)169.52MShares10.72052wk High0.67P/B399.20MFloat Cap3.02052wk Low--Dividend TTM129.40MShs Float64.370Historical High--Div YieldTTM5.16%Amplitude3.020Historical Low3.069Avg Price1Lot Size
Relay Therapeutics Stock Forum
Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival
Relay Therapeutics (RLAY) announced updated interim data for RLY-2608, showing an 11.4-month median progression-free survival in second-line patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at the recommended Phase 2 dose. The study demonstrated a 39% confirmed objective response rate ...
Relay Therapeutics Announces Updated Interim Data for Rly-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival
Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium
Relay Therapeutics (RLAY) announced it will present updated clinical data for RLY-2608 in combination with fulvestrant for treating PI3Kα-mutated, HR+, HER2- locally advanced or metastatic breast cancer at the San Antonio Breast Cancer Symposium (December 10-13, 2024). The presentation, titled 'Efficacy of RLY-2608, a mutant-se...
Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors
Relay Therapeutics (RLAY) and Elevar Therapeutics have announced an exclusive global licensing agreement for lirafugratinib, a potential best-in-class FGFR2 inhibitor for treating FGFR2-driven cholangiocarcinoma and other solid tumors. Under the agreement, Elevar receives worldwide development and c...
2 MINUTES AGO, 8:01 AM EST
VIA GLOBENEWSWIRE
Global licensing agreement grants Elevar Therapeutics worldwide rights to develop and commercialize lirafugratinib (RLY-4008)
Lirafugratinib is a potential best-in-class FGFR2 inhibitor that has shown differentiated efficacy in FGFR2-driven cholangiocar...
$Meta Platforms (META.US)$ shares increased 0.70%, with with option volume of 0.37 million, and calls accounted for 58.2% of the volume. The $585 calls expiring October 4 were traded most actively.
Meta Platforms said on Tuesday that the company will expand artificial intelligence investment in Vietnam, including production of its mixed reality Quest 3S headsets in the country from next...
No comment yet